SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

CORONA Remedies rises on getting EU-GMP certification for Hormone manufacturing facility

29 May 2026 Evaluate

CORONA Remedies is currently trading at Rs. 1693.90, up by 19.00 points or 1.13% from its previous closing of Rs. 1,674.90 on the BSE.

The scrip opened at Rs. 1700.00 and has touched a high and low of Rs. 1700.95 and Rs. 1688.55 respectively. So far 850 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1951.30 on 12-May-2026 and a 52 week low of Rs. 1336.95 on 23-Dec-2025.

Last one week high and low of the scrip stood at Rs. 1,951.30 and Rs. 1,603.95 respectively. The current market cap of the company is Rs. 10,359.91 crore.

The promoters holding in the company stood at 69.00%, while Institutions and Non-Institutions held 9.27% and 21.74% respectively.

CORONA Remedies has received European Union Good Manufacturing Practice (EU-GMP) Compliance Certification for its Hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage (OSD) manufacturing facility at Bhayla in Ahmedabad.

These significant milestones further strengthen CORONA’s global manufacturing and quality credentials, reaffirming its commitment to world-class quality systems, scientific excellence, and manufacturing capabilities aligned with international standards. Achieved with exceptional speed, these accreditations reflect CORONA’s strong quality culture, robust compliance framework, and operational excellence, marking a defining step in its journey to become a globally trusted partner in Hormone & other therapies.

CORONA Remedies is primarily engaged in the business of manufacturing, trading and marketing of pharmaceutical products.

CORONA Remedies Share Price

1747.80 20.40 (1.18%)
16-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.65
Dr. Reddys Lab 1277.05
Cipla 1372.75
Zydus Lifesciences 1078.40
Lupin 2277.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: